<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01072097</url>
  </required_header>
  <id_info>
    <org_study_id>85/2006</org_study_id>
    <nct_id>NCT01072097</nct_id>
  </id_info>
  <brief_title>The Effect of Atorvastatin on Androgens, Glucose Metabolism and Inflammation in Polycystic Ovary Syndrome (PCOS) Women</brief_title>
  <official_title>The Effect of Atorvastatin on Androgen Synthesis, Glucose Metabolism and Inflammation in Women With Polycystic Ovary Syndrome (PCOS). A Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oulu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oulu</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a placebo controlled trial investigating the effect of 6 months atorvastatin 20mg/day
      therapy on androgens, glucose metabolism and inflammatory markers in women with PCOS.

      We assume that during 6 months atorvastatin therapy a significant improvement in
      hyperandrogenism, glucose metabolism and inflammatory markers is observed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      30 women diagnosed for PCOS (aged 30-50 years) are enrolled for the study. 15 women are
      randomized in the atorvastatin group and 15 in the placebo group. The women with PCOS
      participating in the study are required to use safe non-hormonal contraception during the
      medication.

      The study includes transvaginal ultrasonography, serum samples, oral glucose tolerance test
      (OGTT) and intra venous tolerance test (IVGTT) before and after receiving 6 months
      atorvastatin 20mg/day therapy or placebo.

      Measurements for androgen levels, pituitary hormones, glucose, insulin and inflammatory
      markers are performed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Androgen secretion</measure>
    <time_frame>0, 3, 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Glucose metabolism</measure>
    <time_frame>0, (3), 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>0, 3, 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6 months atorvastatin 20mg/day treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>6 months placebo treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Atorvastatin 20mg/day for 6 months</description>
    <arm_group_label>Atorvastatin</arm_group_label>
    <other_name>Lipitor 20mg, Pfizer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for 6 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosed for PCOS (Rotterdam criteria)

          -  aged 30-50 years

          -  safe non-hormonal contraception

        Exclusion Criteria:

          -  use of cholesterol lowering agents

          -  use of antidepressants

          -  use of cortisone medication (p.o.)

          -  use of hormonal contraception

          -  nursing

          -  pregnancy

          -  DM-T2

          -  liver disease

          -  menopause

          -  kidney or liver failure
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Terhi T. Piltonen, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Dept Ob-Gyn, University of Oulu</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Johanna Puurunen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept Ob-Gyn, University of Oulu</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juha S. Tapanainen, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Dept Ob-Gyn, Univeristy of Oulu</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Obstetrics and Gynaecology, University of Oulu</name>
      <address>
        <city>Oulu</city>
        <zip>90014</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2010</study_first_submitted>
  <study_first_submitted_qc>February 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2010</study_first_posted>
  <last_update_submitted>September 6, 2011</last_update_submitted>
  <last_update_submitted_qc>September 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>Juha Tapanainen/Professor</name_title>
    <organization>Dept Ob-Gyn, University of Oulu</organization>
  </responsible_party>
  <keyword>PCOS</keyword>
  <keyword>Atorvastatin</keyword>
  <keyword>Androgens</keyword>
  <keyword>Glucose metabolism</keyword>
  <keyword>Inflammatory markers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Androgens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

